跳至主要内容
临床试验/ISRCTN60323736
ISRCTN60323736已完成1 期

Riociguat in patients with respiratory disease and hypoxia – a proof-of-concept study

ewcastle Hospitals Foundation NHS Trust0 个研究点目标入组 10 人开始时间: 2015年3月11日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
10

研究概览

简要总结

2017 conference abstract in https://erj.ersjournals.com/content/48/suppl_60/pa2436.abstract (added 07/05/2021) (published 21/05/2017)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Age 40 to 80 years, Male and Female
  • 2. Primary diagnosis of either chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) with recent stability
  • 3.Capacity and willingness to provide fully informed consent for participation in the study

排除标准

  • 1. On prescribed oxygen therapy, nitrates (tablets or sublingual), dipyridamole, theophylline, warfarin, clopidogrel, rivaroxaban and dabigatran
  • 2. Other concomitant respiratory diagnoses including asthma, interstitial lung disease (not idiopathic), pulmonary hypertension (of any other aetiology), lung cancer, recent respiratory infection, recent acute pulmonary embolism, recent pneumothora
  • 3. Unable to give written, informed consent
  • Contraindication to spirometry not included elsewhere: recent eye surgery, glaucoma
  • 4. Uncontrolled arterial hypertension (systolic BP > 180mmHg and/or diastolic BP > 110mmHg
  • 5. Systolic BP < 95mmHg
  • 6. Resting awake heart rate < 50 beats per minute or > 105bpm
  • 7. History of uncontrolled atrial fibrillation within 3 months of screening
  • 8. Left heart failure with an ejection fraction less than 40%
  • 9. Hypertrophic Obstructive Cardiomyopathy (HOCM)
  • 10. Proven or suspected active or recent* coronary artery disease
  • 11. Other active atherosclerotic disease: active peripheral arterial disease, stroke within 3 months of screening
  • 12. Significant valvular heart disease
  • 13. History of active or serious haemoptysis/pulmonary haemorrhage
  • 14. Hepatic dysfunction
  • 15. Bilirubin > 2 times ULN at screening and/or
  • 16. ALT or AST > 3 times ULN at screening and/or
  • 17. Albumin < 32g/L/hepatic encephalopathy > grade 1 at screening
  • 18. Renal insufficiency: GFR < 30ml/min
  • 19. Pregnant or lactating women

研究者

发起方
ewcastle Hospitals Foundation NHS Trust

相似试验